3-Month Lab Check on GLP-1: What Improves
Your first follow-up labs -- what to expect and why the early numbers are already encouraging.
Three months on GLP-1 medication marks your first objective checkpoint. While you have been watching the scale, your blood work tells a deeper story -- one of metabolic transformation that goes far beyond pounds lost.
What Typically Improves by 3 Months
Expected 3-Month Improvements
| Marker | Typical Change | What It Means |
|---|---|---|
| Fasting glucose | 5-15% decrease | Improved insulin sensitivity |
| HbA1c | 0.3-0.8% decrease | Better 3-month blood sugar average |
| Triglycerides | 10-20% decrease | Improved lipid metabolism |
| ALT (liver enzyme) | Often improves | Reduced liver fat and inflammation |
| Fasting insulin | 15-25% decrease | Reduced insulin resistance |
| LDL cholesterol | Variable | May take 6+ months for significant change |
Recommended 3-Month Tests
- Comprehensive metabolic panel (CMP)
- Lipid panel
- HbA1c
- Liver function (ALT, AST) -- especially if elevated at baseline
- Weight and vital signs comparison
What NOT to Worry About
At 3 months, you may still be in dose escalation (not yet at full therapeutic dose). Some markers like LDL and inflammatory markers take longer to show improvement. Small fluctuations in kidney markers (creatinine, BUN) are normal during weight loss. Weight loss itself may not yet be dramatic -- many patients see their biggest losses at months 4-8.
What Comes Next
Continue your treatment and lifestyle modifications. Your 6-month labs will show more dramatic improvements as you reach therapeutic doses and accumulate more weight loss. Share your results with your Trimi physician to guide dose adjustments and optimize treatment.
Track Your Transformation
Trimi physicians monitor your labs and adjust treatment accordingly. Semaglutide $99/mo. Tirzepatide $125/mo.
Get StartedMedical Disclaimer
Lab improvements cited are typical ranges; individual results vary. Discuss all lab results with your healthcare provider. Do not adjust medications based on this article alone.
More on GLP-1 lab monitoring
Sources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).